Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

Authors: Rajiv Agarwal, Patrick Rossignol, Alain Romero, Dahlia Garza, Martha Mayo, Suzette Warren, Jia Ma, William B. White, Bryan Williams - The Lancet 2019 cited by 362